Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements
Authors
Goyal, L.Meric-Bernstam, F.
Hollebecque, A.
Morizane, C.
Valle, Juan W
Karasic, T. B.
Abrams, T. A.
Kelley, R. K.
Cassier, P. A.
Furuse, J.
Klumpen, H. J.
Chang, H. M.
Chen, L. T.
Komatsu, Y.
Masuda, K.
Ahn, D. H.
Li, K.
Benhadji, K. A.
Wacheck, V.
Bridgewater, J. A.
Affiliation
Mass General Cancer Center, Harvard Medical School, Boston, MAIssue Date
2022
Metadata
Show full item recordCitation
Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301177.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.4009Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4009Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.4009